Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 6Neoplasms 3Neoplasm Metastasis 2Lymphoma 1Leiomyosarcoma 1

Interventions

Doxorubicin 4Radiotherapy 3belinostat 2Trabectedin 2Gemcitabine 2selinexor 1sargramostim 1peposertib 1pembrolizumab 1olaratumab 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1PTC596 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ifosfamide 1INCB039110 1Fluorouracil 1Erlotinib Hydrochloride 1Dacarbazine 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leiomyosarcoma × olaratumab × Clear all
NCT03437070 2019-03-18

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

University of Miami

Phase 1 Withdrawn
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡